Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide vaccine (groups A, C, Y and W135)
- Development stage
- Unknown
- Lead developer
- AIM Vaccine Co.
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MPSV4 is a quadrivalent meningococcal polysaccharide vaccine developed and manufactured by Ningbo Rongan Biological Pharmaceutical, a subsidiary of AIM Vaccines. It is indicated for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. The vaccine contains purified capsular polysaccharides from each of these four serogroups, which act as antigens to stimulate the host's immune system to produce serogroup-specific bactericidal antibodies. These antibodies provide protection by facilitating complement-mediated lysis of the bacteria. The vaccine is approved for use in China and is typically administered via subcutaneous injection.
- Other names
- ACYW135 Meningococcus Polysaccharide VaccineACYW-135 Meningococcus Polysaccharide VaccineACYW 135 Meningococcus Polysaccharide Vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal polysaccharide vaccine (groups A, C, Y and W135).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide vaccine (groups A, C, Y and W135).